In the study of Horn et al., drugs targeting PI3K/AKT/mTOR and MAPK signaling pathways combined with agents targeting CDK4/6 family protein were identified in their most optimal drug combination against colorectal cancer [42]. This evidence concerns the gene AKT1 and colorectal cancer.